Study of ARO-AAT in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)
Status:
Active, not recruiting
Trial end date:
2023-08-23
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the the safety and efficacy of ARO-AAT Injection
(also referred to as ARO-AAT) administered subcutaneously to patients with alpha-1
antitrypsin deficiency.